Novartis AG’s small molecule phosphoinositide 3-kinase delta (PI3Kẟ) blocker CDZ173, which is in a registration-enabling study, is expected to reach the market in 2022 lastest. Activated Phosphoinositide 3-kinase Delta Syndrome (APDS) is an ultra-rare, debilitating primary immune deficiency which makes carriers of the underlying defect in the PIK3CD gene unable to fight of infections. Currently there is no approved treatment available for PIK3CD overactivity, which occurrs approximately 1-2 per million.
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
AI Alzheimer antibodies bacteria binx health Biosimilar Blood Filter Cancer cardiovascular cell therapy CE Mark clinical trial colorectal cancer Diagnostics Digital Health Drug Discovery ExThera Medical FDA FDA approval funding fundraising glycosylation Halodoc HIV Innovation Licensing M&A medical device medtech microbial microbial DNA microbial RNA microbiome Neuro Novartis pharma Pharming Prescient Metabiomics robots software Therapeutics Therapy USA VIrology women health